NKGen Biotech, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.91 k

Shareholding (Sep 2024)

FII

8.37%

Held by 9 FIIs

DII

87.05%

Held by 4 DIIs

Promoter

2.11%

What does NKGen Biotech, Inc. do?

22-Jun-2025

NKGen Biotech, Inc. is a micro-cap company in the finance industry with no dividend yield and significant negative debt equity and return on equity metrics. Contact details are not available.

Is NKGen Biotech, Inc. technically bullish or bearish?

20-Sep-2025

As of August 8, 2025, NKGen Biotech, Inc. is in a bearish trend with weak strength indicators, despite some mildly bullish signals from the MACD, and has underperformed the S&P 500 with a return of -71.09% compared to the S&P's 17.14%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Finance

Market cap

USD 7 Million ()

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-999,999.00

Return on Equity

-999,999.00%

Price to Book

-0.14

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2024)

Net Profit:

7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-74.04%

6 Months

-88.96%

1 Year

-91.77%

2 Years

-98.91%

3 Years

-99.63%

4 Years

-99.62%

5 Years

0.0%

NKGen Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is NKGen Biotech, Inc. technically bullish or bearish?

As of 8 August 2025, the technical trend for NKGen Biotech, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by daily moving averages and a bearish KST on both weekly and monthly time frames. The MACD shows mildly bullish signals on weekly and monthly charts, but this is overshadowed by the overall bearish indicators. The Bollinger Bands and Dow Theory also reflect a mildly bearish sentiment. Over the past year, NKGen Biotech has significantly underperformed the S&P 500, with a return of -71.09% compared to the S&P's 17.14%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-300.50%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

55.94%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

EV to EBITDA

EV to Capital Employed

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 7 Schemes (2.47%)

Foreign Institutions

Held by 9 Foreign Institutions (8.37%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 119.88% vs -395.52% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.50",
          "val2": "-6.60",
          "chgp": "1.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.20",
          "chgp": "150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "16.80",
          "val2": "-1.60",
          "chgp": "1,150.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6.60",
          "val2": "-33.20",
          "chgp": "119.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -100.00% vs 0.00% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -209.70% vs -2,580.00% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.50",
          "val2": "-23.10",
          "chgp": "-23.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "2.30",
          "chgp": "-69.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-27.70",
          "val2": "-0.20",
          "chgp": "-13,750.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-83.00",
          "val2": "-26.80",
          "chgp": "-209.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-316,181.80%",
          "chgp": "31,618.18%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY

Sep'24

Sep'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.50

-6.60

1.52%

Interest

0.50

0.20

150.00%

Exceptional Items

16.80

-1.60

1,150.00%

Consolidate Net Profit

6.60

-33.20

119.88%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Consolidated Net Profit

YoY Growth in quarter ended Sep 2024 is 119.88% vs -395.52% in Sep 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

0.00

0.10

-100.00%

Operating Profit (PBDIT) excl Other Income

-28.50

-23.10

-23.38%

Interest

0.70

2.30

-69.57%

Exceptional Items

-27.70

-0.20

-13,750.00%

Consolidate Net Profit

-83.00

-26.80

-209.70%

Operating Profit Margin (Excl OI)

0.00%

-316,181.80%

31,618.18%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is -100.00% vs 0.00% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -209.70% vs -2,580.00% in Dec 2022

All Annual Results

Company CV

About NKGen Biotech, Inc.

NKGen Biotech, Inc.

Finance

No Details Available.

Company Coordinates

No Company Details Available

NKGen Biotech, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

What does NKGen Biotech, Inc. do?

Watch in Real-Time

Is NKGen Biotech, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is NKGen Biotech, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2024

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY

Annual Results Snapshot (Consolidated) - Dec'23

About NKGen Biotech, Inc.

Company Coordinates